TVTX Stock Analysis: Why Travere Therapeutics Inc Scored 27% in Stock Value Finder

Travere Therapeutics Inc (TVTX): A Detailed StockValueFinder Educational Review

Overview of Travere Therapeutics Inc (TVTX)

Travere Therapeutics Inc (TVTX) is a biotechnology company operating in the healthcare sector. Biotechnology firms focus on developing innovative medical treatments, often targeting rare or complex diseases. These companies typically invest heavily in research and development (R&D) to bring new therapies to market, which can lead to high growth potential but also significant financial risk.

This article is an educational review from StockValueFinder.com. It examines TVTX using a structured, number-driven approach to help investors understand how to evaluate stocks based on fundamental and valuation metrics. The goal is to provide clear, factual insights—not personal financial advice or predictions about future performance.

Why the StockValueFinder Score Matters

StockValueFinder uses a disciplined scoring system to assess stocks based on key financial and valuation metrics. The overall score for Travere Therapeutics is **27%**, which results in an **AVOID** rating. This score reflects a combination of weak profitability, high valuation, and financial risk factors.

A score of 27% means that, based on the available data, TVTX does not meet the criteria for financial strength, efficiency, or valuation discipline that StockValueFinder typically looks for in high-quality stocks. Scores above 70% are generally considered strong, while scores below 40% indicate areas of concern that may warrant caution.

This review will break down each metric used in the scoring system, explain what the numbers mean, and show why TVTX passed or failed each test.

—

EPS Strength and Consistency

What Is EPS?

Earnings per share (EPS) measures a company’s profitability on a per-share basis. It is calculated by dividing net income by the number of outstanding shares. Consistent or growing EPS over time is often a sign of a healthy, well-managed business.

Why EPS Consistency Matters

StockValueFinder looks for companies with a track record of stable or improving EPS. This consistency suggests that the company can generate profits reliably, which is important for long-term investors. Companies with erratic or declining EPS may face operational challenges, competitive pressures, or financial instability.

How StockValueFinder Evaluates EPS

The system checks for

– Positive EPS in recent quarters or years. – A history of growth or stability. – No significant declines without clear justification (e.g., one-time expenses).

TVTX EPS Test Result: **Did Not Pass**

The exact EPS values for TVTX were not supplied in the available data. However, the system recorded a **fail** for the EPS test. This suggests that TVTX either reported negative earnings, inconsistent earnings, or a pattern of declining profitability.

#### Example for Learning

– **Strong EPS Example:** A company reports EPS of $1.20, $1.35, and $1.50 over three consecutive years. This shows consistent growth. – **Weak EPS Example:** A company reports EPS of $0.80, -$0.20, and $0.50. The negative EPS and volatility raise red flags.

Since TVTX did not pass this test, investors should be cautious about its profitability trends. Without consistent earnings, it becomes harder to justify the stock’s valuation or predict future performance.

—

ROIC and Capital Efficiency

What Is ROIC?

Return on invested capital (ROIC) measures how efficiently a company uses its capital to generate profits. It is calculated as:

**ROIC = (Net Operating Profit After Tax) / (Total Invested Capital)**

ROIC helps investors understand whether a company is creating value with the money it invests in its business.

Why ROIC Matters

A high ROIC (typically 10% or higher) suggests that a company is generating strong returns from its investments. This is a sign of a competitive advantage, efficient management, or a high-margin business. A low or negative ROIC indicates that the company is struggling to generate profits from its capital, which can be a warning sign.

TVTX ROIC: **-5.76%**

Travere Therapeutics has an ROIC of **-5.76%**. This negative figure means the company is not generating enough profit to cover its invested capital. In fact, it is losing money on its investments.

#### What a Strong vs. Weak ROIC Looks Like

– **Strong ROIC Example:** A company with an ROIC of 15% is using its capital efficiently and likely has a competitive edge. – **Weak ROIC Example:** A company with an ROIC of 4% is barely covering its cost of capital, while a negative ROIC (like TVTX) indicates value destruction.

ROIC Test Result: **Did Not Pass**

StockValueFinder generally prefers companies with an ROIC of **10% or higher**. Since TVTX’s ROIC is negative, it fails this test. This is a significant red flag, as it suggests the company is not generating sufficient returns from its R&D investments, operations, or other capital expenditures.

—

Interest Coverage and Financial Safety

What Is Interest Coverage?

Interest coverage measures a company’s ability to pay the interest on its debt. It is calculated as:

**Interest Coverage = (Earnings Before Interest and Taxes) / (Interest Expense)**

A higher interest coverage ratio means the company can easily meet its interest obligations, while a low ratio suggests financial strain.

Why Interest Coverage Matters

StockValueFinder looks for an interest coverage ratio of **6 or higher**. This threshold ensures that the company has a comfortable margin of safety to cover its debt obligations, even if earnings fluctuate.

TVTX Interest Coverage Test Result: **Did Not Pass**

The exact interest coverage ratio for TVTX was not supplied, but the system recorded a **fail** for this test. This suggests that TVTX’s earnings are not sufficient to cover its interest expenses comfortably.

#### Example for Learning

– **Strong Interest Coverage Example:** A company with an interest coverage ratio of 8x can easily pay its interest expenses, even if earnings dip slightly. – **Weak Interest Coverage Example:** A company with a ratio of 2x is at risk of default if earnings decline, as it may struggle to meet its debt obligations.

Since TVTX did not pass this test, it raises concerns about the company’s financial stability and ability to manage its debt load.

—

Debt Payback and Balance Sheet Discipline

What Is Debt Payback?

Debt payback measures how long it would take a company to pay off its total debt using its current operating income. It is calculated as:

**Debt Payback Years = (Total Debt) / (Operating Income)**

A shorter debt payback period (e.g., 3 years or less) indicates a stronger balance sheet and lower financial risk.

Why Debt Payback Matters

StockValueFinder prefers companies with a debt payback period of **3 years or less**. This ensures that the company can quickly reduce its debt burden, freeing up cash flow for growth, dividends, or share buybacks.

TVTX Debt Payback: **-15.30 Years**

Travere Therapeutics has a debt payback period of **-15.30 years**. The negative value indicates that the company is not generating positive operating income. In other words, TVTX is losing money at the operating level, making it impossible to pay down debt with current earnings.

#### What a Strong vs. Weak Debt Payback Looks Like

– **Strong Debt Payback Example:** A company with a debt payback period of 1.5 years can quickly eliminate its debt, reducing financial risk. – **Weak Debt Payback Example:** A company with a debt payback period of 7 years or more (or negative, like TVTX) faces significant financial strain and may struggle to service its debt.

Debt Payback Test Result: **Passed**

Despite the negative debt payback period, StockValueFinder recorded a **pass** for this test. This is unusual, as a negative debt payback period typically indicates severe financial distress. It is possible that the system’s criteria for this test were met due to other factors, such as low absolute debt levels or a specific accounting treatment. However, the negative debt payback period remains a major concern for investors.

—

P/E Ratio and Valuation Discipline

What Is the P/E Ratio?

The price-to-earnings (P/E) ratio measures how much investors are willing to pay for each dollar of a company’s earnings. It is calculated as:

**P/E Ratio = (Stock Price) / (Earnings Per Share)**

A high P/E ratio suggests that investors expect strong future growth, while a low P/E ratio may indicate an undervalued or mature business.

Why P/E Ratio Matters

StockValueFinder prefers a P/E ratio of **15 or lower** for valuation discipline. This threshold helps avoid overpaying for stocks, especially in industries where growth expectations may be overly optimistic.

TVTX P/E Ratio: **56.49**

Travere Therapeutics has a P/E ratio of **56.49**, which is significantly higher than StockValueFinder’s preferred threshold. This means investors are paying $56.49 for every $1 of TVTX’s earnings.

#### What a Strong vs. Weak P/E Ratio Looks Like

– **Strong P/E Example:** A company with a P/E of 8 is trading at a discount to its earnings, which may indicate an undervalued opportunity (assuming the business is healthy). – **Weak P/E Example:** A company with a P/E of 40 or higher (like TVTX) is trading at a premium, which may not be justified unless future growth is exceptional.

P/E Ratio Test Result: **Did Not Pass**

Since TVTX’s P/E ratio is well above 15, it fails this test. This suggests that the stock is expensive relative to its current earnings, and investors may be overpaying for future growth expectations.

—

Moving Average Trend and Entry Timing

What Is the Moving Average Signal?

The moving average signal is a technical indicator that helps investors assess the stock’s trend. It compares the stock’s current price to its moving averages (e.g., 50-day or 200-day) to determine whether the trend is bullish, bearish, or neutral.

Why Moving Average Matters

StockValueFinder uses the moving average signal to gauge the stock’s momentum and potential entry points. A **bullish** signal suggests upward momentum, while a **bearish** signal indicates downward pressure. A **neutral** signal means the stock is trading within a range, and investors may want to watch for a clearer trend.

TVTX Moving Average Signal: **NEUTRAL / WATCH**

Travere Therapeutics has a **neutral / watch** moving average signal. This means the stock is not showing a clear upward or downward trend, and investors may want to monitor it for a potential breakout or breakdown.

Entry Signal: **N/A**

The entry signal for TVTX is **not available (N/A)**. This suggests that the stock does not currently meet the criteria for a favorable entry point based on StockValueFinder’s trend analysis.

#### Example for Learning

– **Bullish Signal Example:** A stock trading above its 50-day and 200-day moving averages may indicate upward momentum. – **Bearish Signal Example:** A stock trading below both moving averages may suggest downward pressure.

Since TVTX’s signal is neutral, investors should exercise caution and avoid making decisions based solely on trend analysis.

—

Overall Financial Strengths and Weaknesses

Strengths

1. **Debt Payback Test Passed:** Despite the negative debt payback period, the system recorded a pass for this test. This may indicate that TVTX has manageable debt levels relative to its industry or other factors. 2. **Biotechnology Sector Potential:** As a biotech company, TVTX operates in a high-growth industry with the potential for significant returns if its drug development efforts succeed.

Weaknesses

1. **Negative ROIC (-5.76%):** The company is not generating sufficient returns on its invested capital, which is a major red flag for profitability and efficiency. 2. **High P/E Ratio (56.49):** The stock is trading at a premium relative to its earnings, which may not be justified given its financial performance. 3. **Failed EPS Test:** The company’s earnings are inconsistent or negative, raising concerns about profitability. 4. **Failed Interest Coverage Test:** TVTX may struggle to meet its debt obligations, indicating financial risk. 5. **Negative Debt Payback Period (-15.30 Years):** The company is losing money at the operating level, making it impossible to pay down debt with current earnings.

—

Risks and Limitations

Financial Risks

1. **Profitability Concerns:** TVTX’s negative ROIC and failed EPS test suggest that the company is not generating consistent profits. This is a significant risk for investors, as profitability is essential for long-term sustainability. 2. **High Valuation:** The P/E ratio of 56.49 indicates that the stock is expensive relative to its earnings. If future growth does not materialize, the stock could face downward pressure. 3. **Debt and Interest Coverage:** The failed interest coverage test and negative debt payback period raise concerns about TVTX’s ability to manage its debt load.

Industry Risks

1. **Biotechnology Volatility:** Biotech stocks are inherently risky due to the uncertainty of drug development. Clinical trials can fail, regulatory approvals can be delayed, and competition can erode market share. 2. **Regulatory Risks:** TVTX’s success depends on gaining approval for its therapies from regulatory bodies like the FDA. Any setbacks in this process could negatively impact the stock. 3. **Market Competition:** The biotech industry is highly competitive, and TVTX may face challenges from larger, more established players.

Limitations of This Analysis

1. **Lack of Detailed EPS Data:** The exact EPS values for TVTX were not supplied, which limits the depth of the profitability analysis. 2. **No Future Predictions:** This review is based on historical and current data. It does not account for future events, such as new drug approvals or changes in management. 3. **No Personal Financial Advice:** This article is for educational purposes only and does not recommend buying or selling TVTX.

—

Educational Conclusion

Travere Therapeutics Inc (TVTX) is a biotechnology company with significant potential but also substantial financial risks. Based on the available data, TVTX does not meet the criteria for financial strength, efficiency, or valuation discipline that StockValueFinder typically looks for in high-quality stocks.

Key Takeaways for Investors:

1. **Profitability Matters:** TVTX’s negative ROIC and failed EPS test indicate that the company is not generating sufficient profits. Investors should prioritize companies with consistent earnings and strong returns on capital. 2. **Valuation Discipline:** The P/E ratio of 56.49 suggests that TVTX is trading at a premium. Investors should be cautious about overpaying for stocks, especially in high-risk industries like biotech. 3. **Financial Safety:** The failed interest coverage test and negative debt payback period raise concerns about TVTX’s ability to manage its debt. Financial stability is critical for long-term success. 4. **Trend Analysis:** The neutral moving average signal suggests that TVTX is not showing a clear trend. Investors should avoid making decisions based solely on technical indicators. 5. **Biotech Risks:** The biotechnology sector is volatile and unpredictable. Investors should carefully assess the risks before investing in biotech stocks.

How to Apply This Analysis to Other Stocks:

– **EPS Consistency:** Look for companies with stable or growing earnings over time. – **ROIC:** Aim for companies with an ROIC of 10% or higher to ensure capital efficiency. – **Interest Coverage:** Prefer companies with an interest coverage ratio of 6 or higher for financial safety. – **Debt Payback:** Look for companies with a debt payback period of 3 years or less. – **P/E Ratio:** Avoid overpaying for stocks by sticking to a P/E ratio of 15 or lower (unless justified by exceptional growth). – **Moving Average:** Use trend analysis as a tool for timing, not as a guarantee of future performance.

This article is for research and educational purposes only. It is not personal financial advice, investment advice, or a recommendation to buy or sell any security. Always conduct your own research and consult with a financial advisor before making investment decisions.

---

Research links: Yahoo Finance | Seeking Alpha | Finviz | SEC Filings